CZ353698A3 - Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje - Google Patents

Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje Download PDF

Info

Publication number
CZ353698A3
CZ353698A3 CZ983536A CZ353698A CZ353698A3 CZ 353698 A3 CZ353698 A3 CZ 353698A3 CZ 983536 A CZ983536 A CZ 983536A CZ 353698 A CZ353698 A CZ 353698A CZ 353698 A3 CZ353698 A3 CZ 353698A3
Authority
CZ
Czechia
Prior art keywords
antibody
seq
sequence
light chain
humanized
Prior art date
Application number
CZ983536A
Other languages
Czech (cs)
English (en)
Inventor
Clive Graham Copley
Michael Derek Edge
Stephen Charles Emery
Original Assignee
Zeneca Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed by Zeneca Limited filed Critical Zeneca Limited
Publication of CZ353698A3 publication Critical patent/CZ353698A3/cs

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
CZ983536A 1996-05-04 1997-04-29 Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje CZ353698A3 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein

Publications (1)

Publication Number Publication Date
CZ353698A3 true CZ353698A3 (cs) 1999-02-17

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ983536A CZ353698A3 (cs) 1996-05-04 1997-04-29 Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje

Country Status (19)

Country Link
US (2) US6277599B1 (enExample)
EP (1) EP0896626B1 (enExample)
JP (1) JP2000510692A (enExample)
CN (1) CN1217750A (enExample)
AT (1) ATE350478T1 (enExample)
AU (1) AU719513B2 (enExample)
BR (1) BR9708910A (enExample)
CA (1) CA2250579A1 (enExample)
CZ (1) CZ353698A3 (enExample)
DE (1) DE69737188T2 (enExample)
ES (1) ES2279539T3 (enExample)
HU (1) HUP9901562A3 (enExample)
IL (1) IL126772A0 (enExample)
NO (1) NO985120L (enExample)
NZ (1) NZ331978A (enExample)
PL (1) PL329871A1 (enExample)
SK (1) SK150298A3 (enExample)
TR (1) TR199802227T2 (enExample)
WO (1) WO1997042329A1 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
IL138022A0 (en) * 1998-02-25 2001-10-31 Dow Chemical Co High affinity humanized anti-cea monoclonal antibodies
WO2000029583A2 (en) * 1998-11-19 2000-05-25 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
AU2186900A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Recombinant synthesis of beta-lipotropin and other peptides
CA2391925A1 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Antibodies
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
EP1283719B1 (de) * 2000-04-22 2007-09-05 PharmedArtis GmbH Apoptotika
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
WO2004078937A2 (en) * 2003-03-04 2004-09-16 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
US7619070B2 (en) * 2003-04-23 2009-11-17 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (IFNAR-1)
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
US8088609B2 (en) * 2004-04-15 2012-01-03 Danisco Us Inc. CAB molecules
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
EP1861425B1 (en) 2005-03-10 2012-05-16 Morphotek, Inc. Anti-mesothelin antibodies
AU2006241099B2 (en) 2005-04-22 2012-04-19 Eisai, Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
JP2010500967A (ja) 2006-07-20 2010-01-14 ザ ジェネラル ホスピタル コーポレイション コンビナトリアルターゲティングを通じたプロトキシンの選択的活性化のための方法、組成物、およびキット
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体，包含其的组合物，及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
US8940303B2 (en) * 2010-01-28 2015-01-27 Glaxo Group Limited CD127 binding proteins
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
EP2968585B1 (en) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EA037749B1 (ru) 2014-10-29 2021-05-18 Тева Фармасьютикалз Острэйлиа Пти Лтд ВАРИАНТЫ ИНТЕРФЕРОНА 2b
CN109476756B (zh) 2016-03-15 2022-05-31 埃泰美德(香港)有限公司 一种多特异性Fab融合蛋白及其用途
JP7241677B2 (ja) 2016-07-19 2023-03-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ４７併用療法
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
CN106749667B (zh) * 2016-12-04 2020-07-14 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的纳米抗体及其应用
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
US12460000B2 (en) 2018-09-07 2025-11-04 Itabmed (Hk) Limited Anti-CD19 and anti-CD3 bispecific antigen binding proteins and uses thereof
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
JP7748935B2 (ja) * 2019-08-27 2025-10-03 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア ＩＬ１３Ｒα２陽性ヒト腫瘍およびイヌ腫瘍を処置するための合成ＣＡＲ
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN112409485B (zh) * 2020-10-21 2022-10-25 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH08509612A (ja) * 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Also Published As

Publication number Publication date
BR9708910A (pt) 1999-08-03
ES2279539T3 (es) 2007-08-16
ATE350478T1 (de) 2007-01-15
EP0896626B1 (en) 2007-01-03
NO985120L (no) 1998-12-29
NZ331978A (en) 2000-05-26
TR199802227T2 (xx) 2000-07-21
WO1997042329A1 (en) 1997-11-13
CN1217750A (zh) 1999-05-26
NO985120D0 (no) 1998-11-03
US6903203B2 (en) 2005-06-07
PL329871A1 (en) 1999-04-12
AU719513B2 (en) 2000-05-11
CA2250579A1 (en) 1997-11-13
US20020142359A1 (en) 2002-10-03
IL126772A0 (en) 1999-08-17
AU2645597A (en) 1997-11-26
JP2000510692A (ja) 2000-08-22
HUP9901562A2 (hu) 1999-08-30
SK150298A3 (en) 1999-04-13
EP0896626A1 (en) 1999-02-17
DE69737188T2 (de) 2007-10-11
US6277599B1 (en) 2001-08-21
DE69737188D1 (de) 2007-02-15
HUP9901562A3 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
AU719513B2 (en) Monoclonal antibody to CEA, conjugates comprising said antibody, and their therapeutic use in an adept system
AU709503B2 (en) Delivery system using mAb 3E10 and mutants and/or functional fragments thereof
US8858950B2 (en) Delivery of pharmaceutical agents via the human insulin receptor
CA2019559C (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
CN101460623B (zh) 新型抗cd98抗体
KR100508136B1 (ko) 화합물
EP0731838B1 (en) Binding structures directed against the ca55.1 antigen
JP3805365B2 (ja) 化合物
AU2004245038A1 (en) De-immunized anti-CD3 antibody
CZ2002935A3 (cs) Protilátky a deriváty protilátek k faktoru IX nebo faktoru IXa
Hoogenboom et al. Cloning and expression of a chimeric antibody directed against the human transferrin receptor.
JPH11511970A (ja) 化学化合物
KR20000010771A (ko) Cea에 대한 모노클로널 항체, 이 항체를 함유하는 접합체 및adept계에서의 치료적 용도
CN100543135C (zh) 单克隆抗体及编码其的基因、药物组合物和诊断试剂
JPH03254691A (ja) 薬剤耐性癌に対するキメラ抗体およびその製造
CZ396599A3 (cs) Genový konstrukt, který kóduje část zaměřující buňku a enzym aktivující proléčivo, pro použití jako léčivo

Legal Events

Date Code Title Description
PD00 Pending as of 2000-06-30 in czech republic